Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells

被引:31
作者
Panieri, Emiliano [1 ]
Saso, Luciano [1 ]
机构
[1] Univ Roma La Sapienza, Dept Physiol & Pharmacol Vittorio Erspamer, I-00185 Rome, Italy
关键词
NRF2-KEAP1; NRF2; inhibitors; reactive oxygen species; oxidative stress; cancer; chemotherapy; redox therapy;
D O I
10.1089/ars.2020.8146
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Significance: The nuclear factor erythroid 2-related factor 2/Kelch-like ECH-associated protein 1 (NRF2/KEAP1) pathway is a crucial and highly conserved defensive system that is required to maintain or restore the intracellular homeostasis in response to oxidative, electrophilic, and other types of stress conditions. The tight control of NRF2 function is maintained by a complex network of biological interactions between positive and negative regulators that ultimately ensure context-specific activation, culminating in the NRF2-driven transcription of cytoprotective genes. Recent Advances: Recent studies indicate that deregulated NRF2 activation is a frequent event in malignant tumors, wherein it is associated with metabolic reprogramming, increased antioxidant capacity, chemoresistance, and poor clinical outcome. On the other hand, the growing interest in the modulation of the cancer cells' redox balance identified NRF2 as an ideal therapeutic target. Critical Issues: For this reason, many efforts have been made to identify potent and selective NRF2 inhibitors that might be used as single agents or adjuvants of anticancer drugs with redox disrupting properties. Despite the lack of specific NRF2 inhibitors still represents a major clinical hurdle, the researchers have exploited alternative strategies to disrupt NRF2 signaling at different levels of its biological activation. Future Directions: Given its dualistic role in tumor initiation and progression, the identification of the appropriate biological context of NRF2 activation and the specific clinicopathological features of patients cohorts wherein its inactivation is expected to have clinical benefits, will represent a major goal in the field of cancer research. In this review, we will briefly describe the structure and function of the NRF2/ KEAP1 system and some of the most promising NRF2 inhibitors, with a particular emphasis on natural compounds and drug repurposing.
引用
收藏
页码:1428 / 1483
页数:56
相关论文
共 50 条
  • [41] Simvastatin activates Keap1/Nrf2 signaling in rat liver
    Habeos, Ioannis G.
    Ziros, Panos G.
    Chartoumpekis, Dionysios
    Psyrogiannis, Agathoklis
    Kyriazopoulou, Venetsana
    Papavassiliou, Athanasios G.
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2008, 86 (11): : 1279 - 1285
  • [42] Nrf2 transcriptional derepression from Keap1 by dietary polyphenols
    Bayele, Henry K.
    Debnam, Edward S.
    Srai, Kaila S.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 469 (03) : 521 - 528
  • [43] Simvastatin activates Keap1/Nrf2 signaling in rat liver
    Ioannis G. Habeos
    Panos G. Ziros
    Dionysios Chartoumpekis
    Agathoklis Psyrogiannis
    Venetsana Kyriazopoulou
    Athanasios G. Papavassiliou
    Journal of Molecular Medicine, 2008, 86
  • [44] Targeting Keap1/Nrf2/ARE signaling pathway in multiple sclerosis
    Michalickova, Danica
    Hrncir, Tomas
    Canova, Nikolina Kutinova
    Slanar, Ondrej
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 873
  • [45] Keap1/Nrf2/ARE signaling unfolds therapeutic targets for redox imbalanced-mediated diseases and diabetic nephropathy
    Adelusi, Temitope Isaac
    Du, Lei
    Hao, Meng
    Zhou, Xueyan
    Xuan, Qian
    Apu, Chowdhury
    Sun, Ying
    Lu, Qian
    Yin, Xiaoxing
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 123
  • [46] Overlooked and valuable facts to know in the NRF2/KEAP1 field
    Kopacz, Aleksandra
    Rojo, Ana, I
    Patibandla, Chinmai
    Lastra-Martinez, Diego
    Piechota-Polanczyk, Aleksandra
    Kloska, Damian
    Jozkowicz, Alicja
    Sutherland, Calum
    Cuadrado, Antonio
    Grochot-Przeczek, Anna
    FREE RADICAL BIOLOGY AND MEDICINE, 2022, 192 : 37 - 49
  • [47] A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer
    Jiang, Chang
    Ward, Nathan P.
    Prieto-Farigua, Nicolas
    Kang, Yun Pyo
    Thalakola, Anish
    Teng, Mingxiang
    DeNicola, Gina M.
    REDOX BIOLOGY, 2022, 54
  • [48] Nrf2 Is a Potential Modulator for Orchestrating Iron Homeostasis and Redox Balance in Cancer Cells
    Zhang, Lingyan
    Zhang, Jian
    Jin, Yuanqing
    Yao, Gang
    Zhao, Hai
    Qiao, Penghai
    Wu, Shuguang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [49] NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
    Hayes, John D.
    McMahon, Michael
    TRENDS IN BIOCHEMICAL SCIENCES, 2009, 34 (04) : 176 - 188
  • [50] Activation of NRF2 by dexamethasone in ataxia telangiectasia cells involves KEAP1 inhibition but not the inhibition of p38
    Biagiotti, Sara
    Bianchi, Marzia
    Rossi, Luigia
    Chessa, Luciana
    Magnani, Mauro
    PLOS ONE, 2019, 14 (05):